Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Setanaxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 known ✓ | Q9NPH5 | 20/20 | 1.00 |
| ▸ | NOX1 known ✓ | Q9Y5S8 | 5/20 | 1.00 |
| ▸ | CYBB | P04839 | 5/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Setanaxib SCHEMBL29375704 | 1.00 | NOX4 (1.00) | NOX4CYBBNOX1NOX5CYP3A4 | |
| Setanaxib SCHEMBL1302603 | 1.00 | NOX4 (1.00) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612593 | 0.87 | NOX4 (0.77) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612522 | 0.86 | NOX4 (0.75) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL1302255 | 0.85 | NOX4 (0.74) | NOX4CYBBNOX1NOX5 | |
| SCHEMBL16612222 | 0.85 | NOX4 (0.74) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931735 | 0.84 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL29523003 | 0.84 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL1302943 | 0.83 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931788 | 0.82 | NOX4 (0.69) | NOX4CYBBNOX1NOX5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 787 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | US GOV VETERANS AFFAIRS (US) | 2026-03-19 | — | — | US | claimed |
| EP-4590314-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | Astellas Gene Therapies, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| US-20250188473-A1 | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | claimed |
| CN-119138406-B | Method for freezing mature dendritic cells | 广州润生细胞医药科技有限责任公司 | 2025-03-07 | — | — | CN | claimed |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | claimed |
| CN-119138406-A | Method for freezing mature dendritic cells | 广州润生细胞医药科技有限责任公司 | 2024-12-17 | — | — | CN | claimed |
| US-20240408186-A1 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES | COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC. | 2024-12-12 | — | — | US | claimed |
| US-20220193117-A1 | Hyaluronic Acid Nanoparticles Comprising NADPH Oxidases Inhibitors and Uses in Treating Cancer | UNIV EMORY (US) | 2022-06-23 | — | — | US | claimed |
| WO-2022132666-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-20220184114-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-06-16 | — | — | US | claimed |
| US-11357760-B2 | Method of treating liver fibrosis | CHEMOCENTRYX, INC. (US) | 2022-06-14 | — | — | US | claimed |
| WO-2022104289-A1 | USE OF PHARMACEUTICAL DOSES OF NIACIN, OR AN ANALOG THEREOF, FOR THE REGRESSION OR REVERSAL OF FIBROSIS AND/OR LIVER CIRRHOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220152012-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-19 | — | — | US | claimed |
| WO-2022087224-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3978020-A1 | SKIN COMPOSITION | National University Corporation Tokyo Medical and Dental University (JP) | 2022-04-06 | — | — | EP | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| EP-3946297-A1 | HYALURONIC ACID NANOPARTICLES COMPRISING NADPH OXIDASES INHIBITORS AND USES IN TREATING CANCER | Emory University (US) | 2022-02-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | NOX4, NOX1, NOX3 | NOX4 1/4885NOX1 2/4885CYBB 4/4885 |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | COL1A1, COL2A1, FN1 | NOX4 156/4885NOX1 97/4885CYBB 87/4885 |
| US-20220193117-A1 | Hyaluronic Acid Nanoparticles Comprising NADPH Oxidases Inhibitors and Uses in Treating Cancer | NOX1, NOXO1, CYBB | NOX4 5/4885NOX1 1/4885CYBB 3/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | NOX4 3/4885NOX1 1/4885CYBB 6/4885 |
| US-11357760-B2 | Method of treating liver fibrosis | CCR2, CMKLR2, CCL2 | NOX4 220/4885NOX1 1175/4885CYBB 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.